Published in Pharmacol Biochem Behav on November 01, 1991
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A (1999) 5.11
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol (2007) 3.16
Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest (2010) 2.32
HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci U S A (1999) 2.32
Self-medication of a cannabinoid CB2 agonist in an animal model of neuropathic pain. Pain (2011) 1.60
The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology (2007) 1.44
Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol Pharmacol (1992) 1.30
Positive allosteric modulation of the human cannabinoid (CB) receptor by RTI-371, a selective inhibitor of the dopamine transporter. Br J Pharmacol (2009) 1.28
Endocannabinoid mechanisms of pain modulation. AAPS J (2006) 1.28
Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. Physiol Behav (2007) 1.22
Discriminative stimulus properties of delta9-tetrahydrocannabinol (THC) in C57Bl/6J mice. Eur J Pharmacol (2009) 1.18
Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Delta(9)-tetrahydrocannabinol in C57BL/6J mice. Psychopharmacology (Berl) (2007) 1.18
1-Pentyl-3-phenylacetylindoles and JWH-018 share in vivo cannabinoid profiles in mice. Drug Alcohol Depend (2011) 1.18
N-arachidonyl maleimide potentiates the pharmacological and biochemical effects of the endocannabinoid 2-arachidonylglycerol through inhibition of monoacylglycerol lipase. J Pharmacol Exp Ther (2008) 1.17
Pharmacological effects of acute and repeated administration of Delta(9)-tetrahydrocannabinol in adolescent and adult rats. J Pharmacol Exp Ther (2006) 1.14
Regional enhancement of cannabinoid CB₁ receptor desensitization in female adolescent rats following repeated Delta-tetrahydrocannabinol exposure. Br J Pharmacol (2010) 1.13
Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids. Life Sci (2013) 1.12
In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects. Br J Pharmacol (2014) 1.10
Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide. Br J Pharmacol (1993) 1.09
Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. Pharmacol Ther (2011) 1.08
Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles. Neuropharmacology (2013) 1.06
Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice. Eur J Pharmacol (2007) 1.06
5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br J Pharmacol (2009) 1.05
Endocannabinoid signalling: has it got rhythm? Br J Pharmacol (2010) 1.04
A review of the interactions between alcohol and the endocannabinoid system: implications for alcohol dependence and future directions for research. Alcohol (2012) 1.02
The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice. Br J Pharmacol (2012) 1.01
Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol. Drug Alcohol Depend (2008) 0.96
Inhalation exposure to smoke from synthetic "marijuana" produces potent cannabimimetic effects in mice. Drug Alcohol Depend (2012) 0.96
CB1 cannabinoid receptor agonists increase intracranial self-stimulation thresholds in the rat. Psychopharmacology (Berl) (2004) 0.96
JWH-018 in rhesus monkeys: differential antagonism of discriminative stimulus, rate-decreasing, and hypothermic effects. Eur J Pharmacol (2014) 0.95
Cannabinoids: a new group of agonists of PPARs. PPAR Res (2007) 0.94
Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects. Pharmacol Biochem Behav (2011) 0.93
Tolerance and cross-tolerance to cannabinoids in mice: schedule-controlled responding and hypothermia. Psychopharmacology (Berl) (2011) 0.92
Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem (2007) 0.92
AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol-Like Effects in Mice. J Pharmacol Exp Ther (2015) 0.90
In vivo effects of synthetic cannabinoids JWH-018 and JWH-073 and phytocannabinoid Δ9-THC in mice: inhalation versus intraperitoneal injection. Pharmacol Biochem Behav (2014) 0.89
Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol. Drug Alcohol Depend (2010) 0.89
Diuretic effects of cannabinoids. J Pharmacol Exp Ther (2012) 0.89
Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents. Psychopharmacology (Berl) (2010) 0.88
Antipsychotic-induced alterations in CB1 receptor-mediated G-protein signaling and in vivo pharmacology in rats. Neuropharmacology (2008) 0.88
To breed or not to breed? Empirical evaluation of drug effects in adolescent rats. Int J Dev Neurosci (2008) 0.87
Endocannabinoid contribution to Δ9-tetrahydrocannabinol discrimination in rodents. Eur J Pharmacol (2014) 0.87
[Cannabinoids--signal transduction and mode of action]. Schmerz (2005) 0.87
3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism. J Pharmacol Exp Ther (2011) 0.86
Age-dependent differences in sensitivity and sensitization to cannabinoids and 'club drugs' in male adolescent and adult rats. Addict Biol (2007) 0.86
Cannabimimetic properties of ajulemic acid. J Pharmacol Exp Ther (2006) 0.86
Sex differences in Δ(9)-tetrahydrocannabinol metabolism and in vivo pharmacology following acute and repeated dosing in adolescent rats. Neurosci Lett (2014) 0.86
Hijacking of Basic Research: The Case of Synthetic Cannabinoids. Methods Rep RTI Press (2011) 0.85
Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception. Drug Alcohol Depend (2009) 0.85
Evaluation of sex differences in cannabinoid dependence. Drug Alcohol Depend (2014) 0.84
Tuberoinfundibular peptide of 39 residues (TIP39) signaling modulates acute and tonic nociception. Exp Neurol (2010) 0.83
Cross-sensitization and cross-tolerance between exogenous cannabinoid antinociception and endocannabinoid-mediated stress-induced analgesia. Neuropharmacology (2007) 0.83
Biochanin A, a naturally occurring inhibitor of fatty acid amide hydrolase. Br J Pharmacol (2010) 0.83
New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis. Br J Pharmacol (2006) 0.83
Simultaneous inhibition of fatty acid amide hydrolase and monoacylglycerol lipase shares discriminative stimulus effects with Δ9-tetrahydrocannabinol in mice. J Pharmacol Exp Ther (2015) 0.83
Tolerance to cannabinoid-induced behaviors in mice treated chronically with ethanol. Psychopharmacology (Berl) (2011) 0.83
"Herbal incense": designer drug blends as cannabimimetics and their assessment by drug discrimination and other in vivo bioassays. Life Sci (2013) 0.82
The CB receptor agonist WIN 55,212-2 fails to elicit disruption of prepulse inhibition of the startle in Sprague-Dawley rats. Psychopharmacology (Berl) (2004) 0.82
Behavioral effects of the novel potent cannabinoid CB1 agonist AM 4054. Pharmacol Biochem Behav (2013) 0.81
In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liability. Prostaglandins Other Lipid Mediat (2009) 0.81
Drug addiction. Curr Top Behav Neurosci (2009) 0.81
Novel 3-substituted rimonabant analogues lack Δ(9) -tetrahydrocannabinol-like abuse-related behavioural effects in mice. Br J Pharmacol (2013) 0.81
The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells. J Biol Chem (2014) 0.81
Tetrahydrocannabinolic acid reduces nausea-induced conditioned gaping in rats and vomiting in Suncus murinus. Br J Pharmacol (2013) 0.81
Enhancement of the behavioral effects of endogenous and exogenous cannabinoid agonists by phenylmethyl sulfonyl fluoride. Neuropharmacology (2011) 0.80
The impact of gonadal hormones on cannabinoid dependence. Exp Clin Psychopharmacol (2015) 0.80
Structural analogs of pyrazole and sulfonamide cannabinoids: effects on acute food intake in mice. Eur J Pharmacol (2012) 0.80
Modulation of pilocarpine-induced seizures by cannabinoid receptor 1. PLoS One (2014) 0.80
Pharmacological characterization of repeated administration of the first generation abused synthetic cannabinoid CP47,497. J Basic Clin Physiol Pharmacol (2016) 0.80
Peripherally selective diphenyl purine antagonist of the CB1 receptor. J Med Chem (2013) 0.79
Synthesis and pharmacology of 1-alkyl-3-(1-naphthoyl)indoles: steric and electronic effects of 4- and 8-halogenated naphthoyl substituents. Bioorg Med Chem (2012) 0.79
Design, synthesis, and biological evaluation of aminoalkylindole derivatives as cannabinoid receptor ligands with potential for treatment of alcohol abuse. J Med Chem (2013) 0.79
Determination of naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in mouse blood and tissue after inhalation exposure to 'buzz' smoke by HPLC/MS/MS. Biomed Chromatogr (2012) 0.79
Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity. Naunyn Schmiedebergs Arch Pharmacol (2011) 0.78
Thermolytic degradation of synthetic cannabinoids: chemical exposures and pharmacological consequences. J Pharmacol Exp Ther (2017) 0.78
Operant nociception in nonhuman primates. Pain (2014) 0.78
Antinociceptive action of isolated mitragynine from Mitragyna Speciosa through activation of opioid receptor system. Int J Mol Sci (2012) 0.78
1-Bromo-3-(1',1'-dimethylalkyl)-1-deoxy-Δ(8)-tetrahydrocannabinols: New selective ligands for the cannabinoid CB(2) receptor. Bioorg Med Chem (2010) 0.77
Detailed analysis of food-reinforced operant lever pressing distinguishes effects of a cannabinoid CB1 inverse agonist and dopamine D1 and D2 antagonists. Pharmacol Biochem Behav (2010) 0.77
Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of in vivo assays in mice. Neuropharmacology (2016) 0.77
Centrally mediated antinociceptive effects of cannabinoid receptor ligands in rat models of nociception. Pharmacol Biochem Behav (2011) 0.77
Behavioral Characterization of the Effects of Cannabis Smoke and Anandamide in Rats. PLoS One (2016) 0.77
Synthesis and pharmacology of 1-methoxy analogs of CP-47,497. Bioorg Med Chem (2010) 0.76
Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke. Pharmaceuticals (Basel) (2010) 0.75
HU-444, a Novel, Potent Anti-Inflammatory, Nonpsychotropic Cannabinoid. J Pharmacol Exp Ther (2015) 0.75
In vitro opioid receptor affinity and in vivo behavioral studies of Nelumbo nucifera flower. J Ethnopharmacol (2015) 0.75
Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-Cigarette Use in Mice. Subst Abuse (2017) 0.75
Tolerance to the Diuretic Effects of Cannabinoids and Cross-Tolerance to a κ-Opioid Agonist in THC-Treated Mice. J Pharmacol Exp Ther (2016) 0.75
Development of a high-performance liquid chromatography-tandem mass spectrometry method for the identification and quantification of CP-47,497, CP-47,497-C8 and JWH-250 in mouse brain. J Anal Toxicol (2014) 0.75
Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 16.31
Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med (1998) 8.62
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev (2002) 8.50
Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol (1995) 8.09
Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci (1991) 5.88
Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol (1988) 5.54
Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A (1990) 5.48
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev (2010) 4.31
Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med (1990) 3.88
Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci U S A (1999) 3.54
An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature (2001) 3.33
Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet (1993) 3.20
Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther (1996) 2.90
A cluster randomised, controlled trial of the value of dental health educators in general dental practice. Br Dent J (2003) 2.72
Inner-city residents, ethnic minorities and primary health care. Postgrad Med J (1983) 2.70
The development of smoking during adolescence--the MRC/Derbyshire Smoking Study. Int J Epidemiol (1983) 2.61
The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther (1994) 2.55
Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology (1980) 2.41
Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther (1993) 2.40
Improving classroom behavior in mentally retarded children through correspondence training. J Appl Behav Anal (1982) 2.39
Three-generation reproductive toxicity study of dietary bisphenol A in CD Sprague-Dawley rats. Toxicol Sci (2002) 2.37
HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci U S A (1999) 2.32
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol (2001) 2.15
Marihuana chemistry. Science (1970) 2.10
The incidence of urinary infection in 5000 pregnant women. Lancet (1966) 2.09
Immunotherapy-responsive seizure-like episodes with potassium channel antibodies. Neurology (2008) 2.06
Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J Neurochem (2000) 2.04
Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J Med Chem (1997) 2.01
A syndrome of loin pain and haematuria associated with disease of peripheral renal arteries. Q J Med (1967) 1.98
Structure-activity relationships of indole- and pyrrole-derived cannabinoids. J Pharmacol Exp Ther (1998) 1.97
The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A (2000) 1.96
Chemical basis of hashish activity. Science (1970) 1.94
Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. J Pharmacol Exp Ther (1997) 1.87
2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A (2001) 1.86
Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol (2007) 1.85
An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol (1998) 1.83
Response deprivation and reinforcement in applied settings: A preliminary analysis. J Appl Behav Anal (1980) 1.83
Early medical use of cannabis. Nature (1993) 1.80
Procedural and methodological issues in telepsychiatry research and program development. Psychiatr Serv (2000) 1.78
Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther (1992) 1.76
Head-to-cervix force: an important physiological variable in labour. 2. Peak active force, peak active pressure and mode of delivery. Br J Obstet Gynaecol (1996) 1.75
Helicobacter pylori possesses two CheY response regulators and a histidine kinase sensor, CheA, which are essential for chemotaxis and colonization of the gastric mucosa. Infect Immun (2000) 1.75
Significance of bacterial and white cell counts in midstream urines. J Clin Pathol (1980) 1.74
Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol (1993) 1.73
Head-to-cervix force: an important physiological variable in labour. 1. The temporal relation between head-to-cervix force and intrauterine pressure during labour. Br J Obstet Gynaecol (1996) 1.67
Coronary endothelial dysfunction after heart transplantation predicts allograft vasculopathy and cardiac death. Circulation (2001) 1.62
Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res (2011) 1.60
ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J (2006) 1.59
Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J Pharmacol Exp Ther (1988) 1.58
Discovery and characterization of endogenous cannabinoids. Life Sci (1999) 1.56
Anandamide may mediate sleep induction. Nature (1997) 1.53
Endocardial infiltrates in the transplanted heart: clinical significance emerging from the analysis of 5026 endomyocardial biopsy specimens. J Heart Lung Transplant (1993) 1.52
Structure-activity relationships in cannabinoids. Pharmacol Rev (1986) 1.52
Development of cross-tolerance between delta 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212. J Pharmacol Exp Ther (1994) 1.52
Repeat organ transplantation in the United States, 1996-2005. Am J Transplant (2007) 1.50
Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. J Neuroimmunol (1997) 1.49
A survey of hantavirus antibody in small-mammal populations in selected United States National Parks. Am J Trop Med Hyg (1998) 1.47
Simultaneous intracoronary ultrasound and Doppler flow studies distinguish flow-mediated from receptor-mediated endothelial responses. Catheter Cardiovasc Interv (1999) 1.46
The localisation of cephaloridine and nitrofurantoin in the kidney. Nephron (1966) 1.45
Delta 9-tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication. Neurosci Biobehav Rev (1992) 1.45
The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. J Am Chem Soc (1971) 1.44
Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem (1993) 1.44
Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine. Br J Pharmacol (1992) 1.44
The cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends Neurosci (1990) 1.42
Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J Pharmacol Exp Ther (1992) 1.41
Cytomegalovirus infections in heart transplant recipients: relationship to immunosuppression. J Heart Lung Transplant (1992) 1.41
Evidence of impaired microvascular function in pre-eclampsia: a non-invasive study. Clin Sci (Lond) (2003) 1.41
Biphasic effects of anandamide. Pharmacol Biochem Behav (1998) 1.41
Recent advances in the chemistry of hashish. Fortschr Chem Org Naturst (1967) 1.40
Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice. J Pharmacol Exp Ther (2005) 1.39
Discordant epicardial and microvascular endothelial responses in heart transplant recipients early after transplantation. J Heart Lung Transplant (1998) 1.39
Structural determinants of the partial agonist-inverse agonist properties of 6'-azidohex-2'-yne-delta8-tetrahydrocannabinol at cannabinoid receptors. Br J Pharmacol (1999) 1.37
Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther (1998) 1.37
Birth weight: nature or nurture? Early Hum Dev (1995) 1.36
Visual estimates of percent diameter coronary stenosis: "a battered gold standard". J Am Coll Cardiol (1988) 1.36
Pharmacological characterization in vivo of the novel opiate, beta-funaltrexamine. J Pharmacol Exp Ther (1982) 1.35
Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia (2007) 1.33
The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain (2001) 1.32
The absolute configuration of delta-1-tetrahydrocannabinol, the major active constituent of hashish. Tetrahedron Lett (1967) 1.30
Developmental differences in the acquisition of tolerance to ethanol. Alcohol (1998) 1.30
Role of matrix metalloproteinases in colorectal carcinogenesis. Ann Surg (2001) 1.30
Effects of dopamine antagonists and accumbens dopamine depletions on time-constrained progressive-ratio performance. Pharmacol Biochem Behav (1998) 1.29
The nonreceptor protein tyrosine phosphatase corkscrew functions in multiple receptor tyrosine kinase pathways in Drosophila. Dev Biol (1996) 1.29
Sensitivity and specificity of assessing coronary bypass graft patency with ultrafast computed tomography: results of a multicenter study. J Am Coll Cardiol (1988) 1.29
Paternity success and the direction of sexual selection in a field population of a semelparous marsupial, Antechinus agilis. Mol Ecol (2003) 1.26
Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur J Pharmacol (2000) 1.23
Design, synthesis, and pharmacological evaluation of ultrashort- to long-acting opioid analgetics. J Med Chem (1991) 1.23